The New York-based company manufactures Inbrija, an inhaler that is FDA approved for Parkinson’s disease symptoms. Merz Therapeutics agreed to purchase Acorda’s assets for $185 million in a “stalking horse” agreement.
Acorda said it decided to file for bankruptcy after reviewing multiple strategic options, according to a news release.
In 2019, the company was at high risk of bankruptcy. The following year, the drugmaker’s employees voted favorably of the workplace, according to a survey conducted by Fortune and analytics firm Great Place to Work. Compared to other biopharma companies, Acorda was ranked No. 6 for its positive work environment.
The bankruptcy proceedings are expected to finalize in June.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
